
Aurinia Pharmaceuticals AUPH
$ 16.08
3.01%
Annual report 2025
added 02-26-2026
Aurinia Pharmaceuticals DSO Ratio 2011-2026 | AUPH
Annual DSO Ratio Aurinia Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 185 | 185 | 39.1 | 39.3 | 65.8 | 3.71 | 422 | 171 | 94.7 | 181 | 73 | 121 | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 422 | 3.71 | 132 |
Quarterly DSO Ratio Aurinia Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 44 | 49.9 | - | 41.7 | 43.4 | 48.1 | - | 48.1 | 42.4 | 43.1 | - | 34.2 | 33 | 75.6 | 49.2 | 44.3 | 38.6 | 59.2 | - | - | - | 560 | 579 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 579 | 33 | 108 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aquestive Therapeutics
AQST
|
103 | $ 4.14 | 0.36 % | $ 443 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
21.2 | $ 8.41 | 4.73 % | $ 230 M | ||
|
Ardelyx
ARDX
|
58 | $ 6.06 | 1.94 % | $ 1.46 B | ||
|
Arcutis Biotherapeutics
ARQT
|
106 | $ 23.83 | 0.85 % | $ 3.03 B | ||
|
Aytu BioScience
AYTU
|
150 | $ 2.65 | -1.12 % | $ 16.6 M | ||
|
I-Mab
IMAB
|
271 | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | ||
|
BioCardia
BCDA
|
101 | $ 1.2 | -0.04 % | $ 8 M | ||
|
BioCryst Pharmaceuticals
BCRX
|
55.1 | $ 9.6 | 6.37 % | $ 1.98 B | ||
|
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | ||
|
Acorda Therapeutics
ACOR
|
48.3 | - | -24.86 % | $ 820 K | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
169 | $ 9.48 | -3.27 % | $ 613 M | ||
|
Adverum Biotechnologies
ADVM
|
222 | - | - | $ 86.2 M | ||
|
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | ||
|
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | ||
|
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
0.114 | - | - | $ 26.5 M | ||
|
BioMarin Pharmaceutical
BMRN
|
88.9 | $ 56.49 | 1.78 % | $ 10.8 B | ||
|
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | ||
|
BioXcel Therapeutics
BTAI
|
103 | $ 1.16 | -2.12 % | $ 14.2 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
28.1 | $ 3.21 | 4.56 % | $ 6.98 B | ||
|
Aravive
ARAV
|
16.8 | - | -13.39 % | $ 1.45 M | ||
|
Catalyst Biosciences
CBIO
|
79.3 | $ 19.97 | 2.94 % | $ 1.78 B | ||
|
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | ||
|
Codexis
CDXS
|
32.9 | $ 1.97 | 7.97 % | $ 172 M | ||
|
Cerus Corporation
CERS
|
47 | $ 1.91 | 2.42 % | $ 364 M | ||
|
Coherus BioSciences
CHRS
|
559 | $ 1.75 | 0.87 % | $ 205 M | ||
|
CureVac N.V.
CVAC
|
13.6 | - | - | $ 867 M |